ShareThis Page

Generic Viagra to hit the market

Ben Schmitt
| Friday, Dec. 8, 2017, 3:12 p.m.
This photo shows Pfizer's Viagra, left, and the company's generic version, sildenafil citrate, at Pfizer Inc., headquarters in New York.
Associated Press
This photo shows Pfizer's Viagra, left, and the company's generic version, sildenafil citrate, at Pfizer Inc., headquarters in New York.

Viagra, the so-called "little blue pill," is about to get a lot cheaper and change colors.

A generic version of the drug, used to treat erectile dysfunction, will be available Monday, according to the Associated Press.

Drugmaker Pfizer Inc. will begin selling the generic version, in white pill form, for about $32 a pill, half of Viagra's price.

Pfizer negotiated a deal four years ago allowing Teva Pharmaceuticals USA Inc. to begin selling a generic version in the United States on Monday, Forbes reported . Therefore, Pfizer plans to release its own white pill at half the current $65-a-little-blue-pill price.

Sildenafil is the active pharmaceutical ingredient in Viagra, which launched in 1998.

Dr. Benjamin Davies, a UPMC urologist, said doctors previously helped patients avoid high Viagra prices by prescribing a cheaper pulmonary hypertension drug, known as Revatio. However, patients would have to take multiple pills to achieve the same effect as one Viagra pill.

"I think it's great that it will cost less," Davies said Friday of the generic form of Viagra. "I'd still like to see it cheaper. I don't think the price is low enough. But I think patients will be happy."

Pfizer's patents have already expired in several other countries . An over-the-counter version of the ED drug has been cleared by United Kingdom regulators.

Demand should be high. More than 18 million men in the United States suffer from erectile dysfunction, according to a study by Johns Hopkins Bloomberg School of Public Health researchers.

"There's no reason why it can't be over the counter," Davies said. "It's safer than aspirin, and I also think that's where we're headed."

Ben Schmitt is a Tribune-Review staff writer. Reach him at 412-320-7991, or via Twitter at @Bencschmitt.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me